LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRXBiotechnology
-$0.39 today
- Market cap
- $1.30B
- Beta
- 0.71
- P/E (TTM)
- -21.4
- EPS (TTM)
- -$1.39
Volume 0.36M
Average 0.23M
LBRX Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
LB Pharmaceuticals Inc Common StockNASDAQ: LBRX
Retained Earnings · Q1 FY2026 · quarter ended Mar 2026
Retained earnings remains negative
Q1 FY2026 retained earnings was -$148.58M, compared with -$114.5M a year earlier.
Context
- Retained earnings amounted to 37.8% of total assets at the end of Q1 FY2026, down 557.1 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -29.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (129.53M) USD
- Year-over-year change
- -24.2%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (129.53M) | -24.2% |
| FY2024 | 2024-12-31 | (104.32M) | -153.1% |
| FY2023 | 2023-12-31 | (41.22M) | -18.0% |
| FY2022 | 2022-12-31 | (34.95M) | — |
Retained Earnings vs competitors
How LBRX compares with its peers on the latest reported figures
- LBRX's Mar 2026 retained earnings of -$148.58M is the 2nd highest of the 10 companies compared; the peer median is -$421.19M.
- Its year-over-year change of -29.8% is the 4th highest of 10, against a peer median of -48.4%.
- Retained earnings amounts to 37.8% of total assets for LBRX, versus a peer median of 81.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $0 | +100.0% | — | 0.0% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | -$148.58M | -29.8% | — | 37.8% |
| Mar 2026 | -$173.23M | -48.0% | — | 62.9% | |
| Mar 2026 | -$227.87M | -48.4% | — | 82.5% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | -$255.09M | -72.6% | — | 51.3% |
| Mar 2026 | -$421.19M | -90.0% | — | 100.6% | |
| Jun 2026 | -$796.74M | -98.0% | — | 0.8% | |
DFTXDefinium Therapeutics, Inc. | Sep 2026 | -$869.72M | -63.4% | — | 81.0% |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | -$1.24B | -21.9% | — | 804.3% |
| Jun 2026 | -$2.31B | -28.5% | — | 199.3% | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding LBRX) | -$421.19M | -48.4% | — | 81.0% | |
Competitors are the stored peer set for LBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
Intrinsic Alpha fair value
Locked
Current Price
$40.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.